Out of the Lab: Operationalizing Cell and Gene Therapy

In this episode, we sit down with Jesus Zurdo, a patient advocate and bioprocessing veteran who has seen the cell therapy journey from both the cleanroom and the hospital bed. We challenge the industry’s obsession with Cost of Goods Sold (COGS) and explore why logistics and manufacturing speed are the true barriers to saving lives.Key topics discussed:The "Wait Time" Crisis: Why 26% of patients die while waiting for a manufacturing slot.Quality over Cost: How low-quality viral vectors lead to higher doses and increased toxicity .The "One and Done" Trap: Why the "cure" narrative may be digging an operational hole for the industry .The Future of In Vivo: How in vivo CAR T could eliminate lymphodepletion and wait times entirely .Show notes:00:07 Why COGS is the wrong metric for accessibility.02:22 The "sCARy" reality of transgene quality and liver toxicity .05:50 The Wait Time Crisis: Breaking down the 26% mortality statistic.16:50 The "One and Done" trap and the necessity of managing cancer as a chronic condition.23:35 The Dream of In Vivo: Removing the logistical and biological hurdles of Ex Vivo.32:20 Point-of-care manufacturing and "Fast CARs" as the operational bridge.

In this episode of the Out of the Lab: Operationalizing Cell Therapy Podcast, host Nico is joined by Claudia Zylberberg to discuss why, despite two decades of innovation and improved manufacturing capability, patient access to cell therapies like CAR T is still limited by adoption and operational issues rather than science. She argues that decentralization should mean smarter, data-trusted orchestration across locations and bringing manufacturing closer to patients through hospital-centered models. Key barriers include physician and hospital discomfort due to training gaps around indications and post-infusion management (e.g., cytokine storm), and fragmented data across EHRs, manufacturers/CDMOs, and post-infusion hospital records. Claudia emphasizes the need for consortia or registries to share blinded data, stronger digital infrastructure, and better integration among hospitals, manufacturers, and payers, with scaling and operational alignment helping reduce costs over time.Chapters:00:20 Industry Status and Decentralization02:11 Physician Adoption Barriers04:22 Training for CAR T Care06:13 Hospitals Offices and Digital Orchestration09:27 Small Hospitals and Data Silos13:24 Blinded Data and AI Potential15:33 Who Owns the Data17:55 Decentralization Beyond Manufacturing19:04 Reimbursement and Payer Dynamics21:31 Integration and Data Sharing Vision22:45 Future Outlook and Closing

Guest: Jennifer Hayne, VP & Head of Biologics Analytics Services at CatalentIn this technical deep dive of the Out of the Lab podcast, we explore the often-overlooked nuances of transferring assays from early-stage research into a GMP (Good Manufacturing Practice) environment. Jennifer from Catalent joins us to discuss why "common sense" in a research lab doesn't always translate to a scalable manufacturing process. We break down the trends in missing documentation, the impact of human variability on results, and how to future-proof your protocols.Key Topics Covered:The Language of Science: Why qualitative terms like "gently resuspend" create variability and how to replace them with specific, measurable steps.Modality Trends: Comparing the "de novo" nature of cell therapy with the emerging platform approaches in gene therapy.The Antibody Renaissance: How bispecifics and ADCs (Antibody Drug Conjugates) are requiring more complex technical discussions than traditional antibodies once did.Scientist-to-Scientist Collaboration: When documentation isn't enough, how Catalent uses site visits to identify hidden sources of variability.Best Practices for Future Transfers: -   Why you need at least two sources for critical raw materials. -   Testing the "limits" of your assay (e.g., what happens at 10 minutes instead of 5?). -   Designing for the 8-hour workday vs. the 48-hour postdoc marathon.Show Notes00:02 - IntroductionNicholas Crudele welcomes Jennifer, VP at Catalent, to discuss trends in incoming procedures and assay transfers.00:39 - Identifying Incomplete DocumentationEarly-stage clients often have incomplete documentation from a GMP perspective, even if it is sufficient to run an initial assay.A significant trend in missing information is the lack of specificity for individual steps, often due to assumptions made by early-stage researchers.02:18 - Human Variability and Standardized TechniquesHuman variability is a major factor in lab results, as different individuals may perform tasks like pipetting or vegetable cutting differently.GMP scientists can help identify where increased specificity is needed to control this variability.Vague qualitative terms, such as "gently resuspend," are a common source of misunderstanding.04:46 - Best Practices for Resolving VariabilityLabs use stringent techniques to reduce variability, such as changing vague language to specific instructions (e.g., "invert the tube three times").If standardized techniques are insufficient, scientist-to-scientist collaboration, including site visits to observe techniques firsthand, is the next step.07:27 - Modality-Specific ChallengesCell Therapy: Every assay is often unique (denovo) and requires technical discussion and experimentation. These materials are sensitive with short shelf lives.Gene Therapy: This modality is increasingly using more stable, platform-type approaches with less variability.Antibodies: While established, new innovations like bispecifics and ADCs are requiring closer technical discussions than in the past.09:37 - The Benefits of Platform TechnologiesPlatform approaches allow for faster and more cost-effective processes by repeating established exercises with minor changes.Working with the same lab over time allows for better tracking and quicker resolution of recurring method challenges.11:47 - Advice for Future Tech TransfersRaw Materials: Ensure critical raw materials are not single-sourced; ideally, have at least two tested sources to avoid supply chain disruptions.Test Assay Limits: Experiment with the timing and limitations of steps (e.g., what happens if a five-minute step is done for ten minutes?) and document the findings for the service provider.Staffing Realities: Consider the practicality of running assays long-term; designs requiring 48 hours of continuous attention are expensive to staff in a traditional GMP lab.

In this episode, we sit down with guest Paul Chun to explore the complex operational challenges within the cell and gene therapy sector. Chun grounds the conversation in the powerful story of Melinda Bachini, the first GI tumor patient to receive tumor-infiltrating lymphocyte (TIL) therapy for cholangiocarcinoma. Despite her success over a decade ago, Chun explains why this life-saving process remains largely inaccessible.We dive deep into the business and operational hurdles of biotech, discussing why companies often pass on niche diagnoses, the intense resource realities of clinical trial design, and why high attrition rates mean fewer than one in ten eligible patients actually make it to treatment. Chun also breaks down the geographic and manufacturing bottlenecks that persist today, noting that while industry leaders have massively expanded their manufacturing capacity, upstream bottlenecks and "last mile" access issues keep actual market adoption plateaued. Discover how new models building standalone clinics aim to expand the catchment area for patients, and learn about the biotech social contract that justifies the cost of high innovation.Chapters / Timestamps:0:00 - 00:33: Introduction and a look at operational challenges in cell and gene therapy.00:33 - 03:33: The story of Melinda Bachini and the specific challenges of cholangiocarcinoma.03:33 - 06:14: Operational and clinical advocacy, featuring Dr. Simon Turcotte's role in Bachini's treatment.06:14 - 09:55: Biotech investment, market dynamics, and how patient advocacy shifts the calculus for niche diagnoses.09:55 - 14:30: Clinical trial design realities, high patient attrition rates, and new TCR-based developments.14:30 - 17:15: Geographic barriers, the high burden of finding trials, and patient access.17:15 - 21:18: Manufacturing capacity expansion vs. upstream bottlenecks and market adoption.21:18 - 28:54: Solving the "last mile" with new clinical models like NexCure.28:54 - 34:10: Supply chain risks in the last yards of the last miles and cultural shifts among specialists like rheumatologists.34:10 - 41:25: The "railroad" infrastructure analogy and the complications of cross-border trial participation.41:25 - 51:44: Financial friction at clinical centers and RA Capital’s "biotech social contract".51:44 - 01:01:20: The high-risk nature of biotech and the critical power of patient stories.

Why does a process that works perfectly in a university lab suddenly fail when it hits a manufacturing facility?In this episode, we sit down with François-Xavier (FX) Lacasse, a 28-year industry veteran, to unpack the notorious friction of tech transfer. We dive into the fundamental language barrier between academia ("research for research") and industry ("research for development"), and why strict GMP/GLP compliance is such a difficult bridge to cross.FX shares some brilliant analogies to explain the reality of scaling up like why changing the pan you’ve cooked a recipe in for 15 years suddenly ruins the dish, or how failing to document a seemingly obvious detail (like the exact temperature of the water) leads to massive reproducibility failures in biotech with a much higher cost than a burnt omelet.Ultimately, it comes down to a simple truth: you don't know what you don't know.In this episode, we cover:- Understanding the physical realities of scaling from an Eppendorf tube to a bioreactor.- The danger of tacit knowledge and unwritten steps in Standard Operating Procedures.- Why documentation is the ultimate crux of successful tech transfer.- How early-stage oversights compound into massive costs during clinical trials.Show Notes:[00:00:22] – Introduction: FX’s background and 28 years of experience in pharmaceutical development.[00:01:26] – The Language Barrier: Understanding the massive gap between "Research for Research" (academia) and "Research for Development" (industry).[00:02:27] – Why you must involve Contract Development and Manufacturing Organizations (CDMOs) as early as possible to anticipate operational pitfalls.[00:04:21] – The Water Temperature Dilemma: How unwritten, tacit knowledge ruins reproducibility when handing off a procedure to another operator.[00:07:35] – Why comprehensive documentation is the absolute "crux of the matter" in tech transfer.[00:12:42] – The massive financial impact of failing to document operational details before hitting multi-million dollar clinical trials.[00:18:59] – The "Cooking Pan" Analogy: Why scaling up from an Eppendorf tube to a bioreactor breaks your process due to heat and mass transfer changes.[00:20:10] – "You don't know what you don't know" – Uncovering the hidden traps in early-stage process development.Connect with us on LinkedIn:Nicholas Crudele (host): François-Xavier (FX) Lacasse (guest):learn how Method Made addresses documentation challenges for tech transfer:

In this episode, host Nico sits down with repeat guest Lee Buckler to tackle the "80/20" problem in cell and gene therapy: the fact that while 80% of patients are treated in community settings, CAR-T therapies are currently stuck in high-level academic centers. We explore the history of patient access from the stem cell transplant model to the lessons learned from Dendreon’s Provenge and map out the infrastructure needed to bring these cures to the local level.From the "10-mile rule" of patient attrition to the massive financial hurdles of carrying multi-million dollar therapies on a hospital’s books, this conversation digs into the operational reality of scaling life-saving scienceKey Discussion PointsThe 10-Mile Rule: Why every 10 miles of distance from a treatment center results in a 6.2% drop in the likelihood of a patient receiving CAR-T.Infrastructure vs. Business Hurdles: Analyzing why the $500,000 to $3 million upfront cost of therapy creates massive cash-flow barriers for community hospitals.Decentralizing the "Vein-to-Vein" Process: How Blood Centers of America (BCA) and FACT are establishing new standards for local apheresis and infusion.Safety and Remote Monitoring: How wearable tech and reduced FDA REMS requirements are allowing patients to recover at home sooner.The Future of Cost: A look at how non-profit models and 5-year ROI data are shifting the payer landscape.Show Notes00:21 – The dual history of cell therapy: Stem cell transplants vs. Provenge.05:43 – The community access gap: Why CAR-T sales have plateaued at 20%.11:48 – Expanding into autoimmune: Why local delivery is no longer optional.19:30 – Logistics and Cryopreservation: Building a national infrastructure.34:33 – Financial bottlenecks and the reality of reimbursement.51:41 – Advancements in remote monitoring and patient safety.58:48 – Insurance, ROI, and the rise of generic models.

In the current investment landscape, the "cool science" era of Cell and Gene Therapy is over. Investors have moved from unbridled optimism to rigorous risk management, yet many IP-backed companies still treat manufacturing as an afterthought, a strategic error that kills margins and delays clinics.In this episode, Nico sits down with Silvio Tiziani, CEO of CCRM Australia, to dissect the "Manufacturability Gap": the critical friction point where regulatory complexity and documentation failures amplify costs.We discuss the business case for early operational rigor, including:The Financial Reality of Rework: Why failing to consider GMP requirements during R&D leads to the ultimate nightmare scenario: returning to the lab bench for total process redesign.The "Widget" Investment Thesis: Silvio explains why the Australian market favors modular, versatile "widgets" over the "single magic box" approach and why this versatility makes for a more attractive, de-risked financial asset.From Founder to Executive: The necessary mindset shift from academic curiosity to commercial competence, and why your pitch must pivot from "technical novelty" to "risk management" to resonate with today's circumspect investors.Join us to learn how to transform operations from your biggest liability into your greatest asset.

"The number one hashtag on everybody's lips is patient accessibility."In this pre-episode teaser, we dive into the sobering reality of the "80/20 Gap" in cell and gene therapy. While the industry has celebrated the arrival of highly curative CAR T-cell therapies, a massive logistical wall has been hit. Lee Buckler joins us to unpack why sales of these "wonderful widgets" are flattening just as they should be scaling.We discuss:The Geographic Divide: Why 80% of cancer patients treated in community healthcare settings are effectively locked out of therapies available only at advanced medical centers (AMCs).The flattening of CAR T: A look at why adoption has stalled at 20%—the exact percentage of patients with easy access to city-center hubs.Beyond the Science: Why the "attractive option" of a cure disappears when a patient faces a five-hour drive, three weeks of city living costs, and a lack of local support systems.The Path to Decentralization: How "boxed-in" physical systems and operational engineering are working to bring manufacturing and processing closer to the patient’s home.If we don't move the therapy to the patient, we leave 80% of the population behind. Join us as we explore the infrastructure and "contractual engineering" required to break CAR-T out of the ivory tower and into the community. Stay tuned for the full episode.

"The tradition is we start with open manual processes: flasks and clean rooms, thinking we can automate and scale and worry about cost of goods later."In this episode, Lee Buckler (Cell Therapy Group) and Nicholas Crudele (Method Made) explore why the "science project" phase of Cell & Gene Therapy often leads to a tech-transfer dead end. But the answer isn’t necessarily locking your process into a rigid, all-in-one "black box" early on.Lee argues for a different path: the "daisy chain" of technologies. Instead of one box that does everything (and limits innovation), the future of the lab is a series of specialized "widgets" digitally connected to ensure compliance without sacrificing flexibility.We discuss how these widget technologies act as the digital glue for this daisy chain, capturing manual breakthroughs today and turning them into the automated, scalable protocols of tomorrow.Highlights:Why the "worry about it later" mentality around manufacturing is a company killer.The "One Box" vs. "Daisy Chain" debate: Why flexibility wins in R&D.

If your process relies on the "golden hands" of a specific scientist, you don't have a product, you have a research project. Nicholas Crudele and Arnaud Deladeriere discuss the critical leap from academic science to GMP manufacturing in cell and gene therapy.We cover:What is CMC? (A primer for founders) .Why the "Product is the Process" mindset fails in cell therapy.How to use "process parameters" as dials to control patient variability.Why you should use GMP materials as early as possible.

What exactly is CMC, and why is it the backbone of pharmaceutical quality? In this episode, Nicholas sits down with Jeffrey Seres to break down the complexities of Chemistry, Manufacturing, and Controls for early-stage founder-scientists.From the friction between aggressive VC timelines and operational realities to the future of documentation, we cover the critical gaps in moving from R&D to commercial manufacturing.Topics covered:Defining CMC: The control and oversight governing manufacturing quality.The Strategy Gap: Why rushed timelines destroy CMC strategy and how to mitigate "Time vs. Money" arguments with investors.Board Composition: Why startups need operational expertise, not just bankers and academics, on their boards.The Future of Docs: Why putting paper on an iPad isn't true digitization—and why full process automation is the real goal.

Are you an R&D-focused founder who thinks of manufacturing as a problem for "later"? This episode is a critical wake-up call.CMC expert and Managing Director David Bruehlmann joins the podcast to explain why a staggering number of promising therapies fail due to CMC issues and how treating "details" as an afterthought can lead to catastrophic failures.We dive into the story of a real-world tech transfer that failed, not because of the equipment, but because of a single, un-documented variable: the light exposure in the lab.This conversation is essential listening for any scientist, engineer, or founder preparing to scale their process.In this episode, you will learn:What CMC Strategy Is: Why it's not an "afterthought" but a strategic asset that must be built from day one.The "Quality by Design" Mindset: How to work backward from the patient to define your critical process parameters and control strategy.How to Choose a CDMO: Why the right partner is about cultural fit, size, and experience—not just the lowest cost.Why CGT is Harder: The fundamental difference between biologics ("the process is the product") and cell therapy ("the cell is the product").The R&D vs. Engineering Mindset: The critical (and necessary) culture clash between scientists focused on results and engineers focused on robustness.If you would like to suggest future episode topics and/or guests, get in touch on LinkedIn

Imagine your cell therapy is nearing Phase 3, but a multi-million dollar manufacturing run fails. The reason? A critical, undocumented step from your pre-clinical R&D was lost in translation years ago. This isn't a scientific failure; it's a business failure, and the seeds are often planted long before you scale. Your company's most valuable asset: the unwritten expertise of your scientists, could be the very thing that puts your clinical success at risk.In this episode, we talk with Akshay Ravindranath, a manufacturing science and technology (MSAT) specialist with 10 years of frontline experience navigating the treacherous gap between R&D innovation and GMP execution. He reveals how seemingly minor details in the lab become major sources of technical risk. These risks lead to delays, and budget overruns during late-stage clinical manufacturing.For CEOs and CTOs, this conversation is not just about documentation, it's about strategic foresight. Listen to this episode to understand how to identify and secure your most critical intellectual assets now to de-risk your journey to Phase 3 and protect your company's valuation.Looking for a documentation solution to derisk before manufacturing? Drop us a line

Beyond the Brochure: Mastering the CDMO Partnership for Successful Tech Transfer with Klaus DörreHow do you choose the right CDMO beyond a slick brochure? And once you do, how do you bridge the critical gap between brilliant R&D and the disciplined realities of GMP manufacturing?In this episode, we're joined by Klaus Dörre, a seasoned professional with deep experience across cell and gene therapy and biologics. Having worked on both the innovator and the CDMO side, Klaus offers a rare 360-degree view of the tech transfer process.We dive into the essential, yet often overlooked, elements of a successful partnership, including the mindset shift required to move from the lab to the plant.In this episode, you will learn:The green flags to look for when selecting a manufacturing partner.Why robust analytics and well-defined potency assays are non-negotiable, even in early phases.The crucial difference between documenting research experiments and writing GMP-ready protocols and SOPs.How to build a relationship based on trust and transparency, turning your CDMO from a simple vendor into a true strategic partner.Key advice for early-stage companies on de-risking their CMC strategy to avoid costly delays.This conversation is a must-listen for founders, CMC leaders, and scientists on the journey from discovery to clinical production. If you are approaching your first tech transfer, see how we can help.

From Data to Scale: How Workplace Silos Break Bioprocessing ModelsIn this episode of Method Made, host Nicholas Crudele sits down with digital bioprocessing expert Dr. Moritz von Stosch to uncover why even the most sophisticated bioprocessing models fail when workplace silos disconnect the people who run experiments from those who analyze the data.What You'll Learn:Why analytical variations of 10-20% still plague new modalities in cell and gene therapyHow separation between operators, sample analyzers, and modelers introduces dangerous assumptionsWhy standardization gaps across sites and raw material lots sabotage process developmentThe hidden scaling challenges that have persisted since 2002 and continue to impact gene therapy manufacturingKey Insights:Dr. von Stosch reveals how the separation of tasks between people who run processes, analyze samples, and model data creates a cascade of documentation errors and missed assumptions. From transfection efficiency challenges to capsid filling ratios, he explains why "if we didn't document it, if we didn't measure it, then we'll have a hard time with the modeling."Critical Takeaway: Process development should focus on answering specific questions, not modeling for modeling's sake. As Moritz emphasizes: "If you have a model which is good enough to answer the question at hand, that model is good enough."Perfect for: Cell and gene therapy process development engineers, manufacturers, operations and technical leaders wrestling with scale-up challenges.Guest: Dr. Moritz von Stosch brings 20+ years of digital bioprocessing expertise from academia and industry, including leadership roles at GSK and as Chief Innovation Officer at Dathera, specializing in hybrid modeling for bioprocess optimization.Method Made explores operational challenges in bioprocessing with a focus on cell and gene therapy manufacturing.

In the high-stakes world of cell and gene therapy, we assume our challenges are unique. But what if the biggest threat to your tech transfer is a universal problem your team is blind to?In this episode of the Method Made podcast, Nicholas talks with David Horesh, a CEO who witnesses the same critical communication failure across dozens of industries—from aerospace and defense to cutting-edge biotech. The problem? Scientists and engineers are not speaking the same language, and it's killing innovation.David's cross-domain experience provides a unique set of "meta-lessons" for the cell and gene therapy space. We funnel his global insights to reveal what CGT teams can learn from mistakes made in entirely different fields.This episode is a masterclass for CGT professionals on:The Universal Blind Spot: Recognizing the hidden language gaps that even the most specialized teams take for granted.Beyond Pharma: How communication breakdowns in mining and quantum physics offer a blueprint for what to fix in your lab.De-Risking Your Tech Transfer: Why understanding this universal communication flaw is a critical de-risking strategy for scaling therapies from R&D to manufacturing.The Real Root Cause: Moving beyond SOPs to see how these language gaps create the operational friction that stalls your timeline before a process is ever documented.If you work in cell and gene therapy, this conversation offers an invaluable outside perspective. It exposes the fundamental communication challenges you didn't know you had and provides a new framework for ensuring your science translates flawlessly into scalable manufacturing.

Ever wonder why cell and gene therapy manufacturing is so expensive? CDMO veteran Steven Keizer (15+ years experience) reveals a shocking operational reality: these procedures literally require two people to do what should be a one-person job.In this episode, Steven breaks down:Why sterile manufacturing forces operators to work with a dedicated scribeHow this violates FDA documentation requirements (but is necessary for patient safety)The fundamental disconnect between R&D teams who want blank pages and operators who need templatesWhen biotech companies should start thinking about tech transfer (hint: much earlier than you think)Quality by design principles that can save millions in failed engineering runsSteven has worked across large pharma and CDMOs, giving him unique insight into both sides of the tech transfer equation. Whether you're scaling your first process or your tenth, this conversation will change how you think about documentation.Key topics: Tech transfer, SOP documentation, cell and gene therapy, GMP manufacturing, quality by design, CDMO operationsmethodmade.ca

I asked Marina Goldfield this exact question on my latest podcast episode. Marina has 20 years of hands-on experience in biological manufacturing.Her answer was unequivocal:"Absolutely everything needs to be written down. There is no level of detail that's going to be too much. In my experience, it's always not enough."Marina explained that teams consistently discover missing details after problems occur: "You always figure out at the end like, oh, we should have written this down."The root cause? Not having detailed conversations during the tech transfer process.When it comes to cell culture, Marina emphasized: "It unfortunately all matters and it's all cumulative. All of these little changes collect together and have a synergistic effect."For biotech companies approaching their first tech transfer: Don't underestimate the level of detail required. What seems like "obvious" knowledge to your team can be the missing piece that causes expensive batch failures downstream.The takeaway: If you're questioning whether to document something - document it. According to Marina, there's no such thing as too much detail in tech transfer.

Pharma consultant Michele Bruschi breaks down why 80% of CDMOs and biotechs are still managing critical operations with spreadsheets and PDFs - and how this data crisis is creating massive competitive advantages for the companies that solve it.In this episode, we explore:Why "endless searching" for SOPs is costing weeks on every projectHow disconnected systems create operational chaos across the industryWhy efficiency and speed have replaced capacity as key differentiatorsThe hidden costs of fragmented data management (13:49)What operational differentiation actually looks like in practice (20:08)Michele's prediction on which companies will survive the current market consolidationMichele brings insider perspective on the pharmaceutical industry's data management challenges and reveals why now is the critical moment for digital transformation in bioprocessing.Whether you're a biotech approaching tech transfer or a CDMO looking to differentiate, this conversation explains the operational realities shaping partnership decisions today.Guest: Michele Bruschi, Pharmaceutical Industry ConsultantHost: Nicholas Crudele, Method Made

Cell and gene therapy faces a brutal reality: while traditional drugs make millions of doses per batch, personalized medicine makes one dose per patient. Yet each dose requires the same documentation burden - resulting in 16 three-ring binders and over 1,000 pages of paperwork per batch.In this episode, Jason Foster from Ori Biotech breaks down two critical bottlenecks killing industry scale-up:The Equipment Mismatch:Academic labs develop therapies using T-flasks and manual toolsCDMOs use completely different manufacturing equipmentCompanies must rebuild their entire process during tech transferNormal timeline: 9-12 months per transferThe Documentation Nightmare:Order of magnitude more batches than traditional biologicsSame regulatory documentation requirements per batchTwo people manually reviewing every pageMost facilities still operating on paperJason shares how Ori reduced one tech transfer from 9-12 months to 2 weeks by standardizing equipment across research and manufacturing: "Tech transfer becomes pushing a button - the protocol transfers to another system that still knows what to do."We also discuss the "curse of knowledge" problem - when PhD experts leave (average cleanroom retention: less than 1 year), critical tribal knowledge walks out the door.Key insights on why the industry needs tools built specifically for personalized medicine, not retrofitted from 20-year-old biologics infrastructure.Guest: Jason Foster, Ori BiotechHost: Nicholas Crudele, Method Made